Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|June 14, 2021

A Welcome Addition to the Child and Adolescent ADHD Armamentarium

Author(s)Ann Childress, MD

This new medication is a huge leap forward for treating attention-deficit/hyperactivity disorder.

Ann Childress, MD, talks about Qelbree and the importance of its approval by the US Food and Drug Administration.

Dr Childress is a practicing psychiatrist with a subspecialty in child and adolescent psychiatry, clinical researcher, and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

ByHeidi Anne Duerr, MPH

August 12th 2026

fullcirclephotos/Adobe Stock

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

ByJessica Walters

August 11th 2026

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

ByGerald A. Maguire, MD

August 11th 2026

stuttering

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

brain

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

ByGerald A. Maguire, MD,Heidi Anne Duerr, MPH,Shahriar SheikhBahaei, PhD,Yoshikazu Kikuchi, MD, PhD,Lisa LaSalle PhD, CCC-SLP,Thomas J. Valente, MD,Anelise Junqueira Bohne, PhD, SLP,Tiago Proença dos Santos, MD,Gonçalo Leal, SLP,Devin Binder, MD, PhD,Gustavo Alva, MD, DFAPA,Greg Mattingly, MD

August 10th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial